Immune system clues guide lighter chemo in breast cancer trial

NCT ID NCT07074106

Recruiting now Disease control Sponsor: D'Or Institute for Research and Education Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a more personalized chemotherapy plan for women with early-stage triple-negative breast cancer. The treatment is adjusted based on immune system activity in the tumor and imaging results. The goal is to see if a lighter chemo can still be effective, reducing side effects while keeping cancer from returning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Instituto D'Or de Pesquisa e Ensino de Brasília
RECRUITING

Brasília, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••
Instituto D'Or de Pesquisa e Ensino de Curitiba
NOT_YET_RECRUITING

Curitiba, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••
Instituto D'Or de Pesquisa e Ensino de Salvador
RECRUITING

Salvador, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••
Instituto D'Or de Pesquisa e Ensino de São Paulo
RECRUITING

São Paulo, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••
Instituto D'Or de Pesquisa e Ensino do Rio de Janeiro
RECRUITING

Rio de Janeiro, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.